Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on July 31, 2025. The report discloses preliminary unaudited financial results for the three-month period ended June 30, 2025, and details a recent equity financing transaction completed in July 2025.
Key Financial Metrics
- Net Loss (Q2 2025): Approximately $900,000 (preliminary estimate).
- Cash and Cash Equivalents (as of June 30, 2025): Approximately $800,000.
- Cash and Cash Equivalents (as of July 30, 2025): Approximately $4.5 million.
- Recent Financing: Issued 5.5 million shares of common stock for gross proceeds of approximately $3.8 million.
- Revenue, Margins, and Debt: The filing text does not provide clear values for revenue, profit margins, or specific debt obligations.
Material Changes
The most significant change reported is the substantial increase in liquidity following the June 30, 2025 period. Cash balances rose from approximately $800,000 to $4.5 million due to the issuance of 5.5 million shares under an existing "equity line of credit" (Securities Purchase Agreement with C/M Capital Master Fund, LP) between July 10 and July 30, 2025.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds are expected to be used for general corporate and working capital purposes, including the payment of outstanding trade payables.
- Unaudited Status: Management emphasizes that the net loss and cash figures are preliminary estimates. They have not been audited, reviewed, or compiled by Ernst & Young LLP.
- Forward-Looking Caution: The filing explicitly states that these estimates are not a substitute for GAAP financial statements and may vary from actual results. Management assumes no duty to update these estimates except as required by law.
- Regulatory Exemption: The share issuance was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b).
Investor Verification Checklist
- Verify the final audited Q2 2025 financial statements to confirm the $900,000 net loss and $800,000 cash position.
- Confirm the exact number of shares issued and final proceeds from the equity line of credit transaction.
- Review the status of outstanding trade payables mentioned as a primary use of the new capital.
- Check for any subsequent filings regarding adjustments to the preliminary estimates provided in this 8-K.